Kauser M. Akhoon

Array ( [id] => 11668404 [patent_doc_number] => 20170157124 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-08 [patent_title] => 'COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/438277 [patent_app_country] => US [patent_app_date] => 2017-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 35648 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15438277 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13369105 [patent_doc_number] => 20180236093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => HERCEPTIN(r) ADJUVANT THERAPY [patent_app_type] => utility [patent_app_number] => 15/428807 [patent_app_country] => US [patent_app_date] => 2017-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29182 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15428807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11589725 [patent_doc_number] => 20170114137 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-27 [patent_title] => 'ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS' [patent_app_type] => utility [patent_app_number] => 15/401843 [patent_app_country] => US [patent_app_date] => 2017-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 38219 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15401843 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11554179 [patent_doc_number] => 20170100425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-13 [patent_title] => 'BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT' [patent_app_type] => utility [patent_app_number] => 15/386887 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 10219 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15386887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11554178 [patent_doc_number] => 20170100424 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-13 [patent_title] => 'BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT' [patent_app_type] => utility [patent_app_number] => 15/386781 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 11897 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15386781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11469608 [patent_doc_number] => 20170056391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-02 [patent_title] => 'COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS' [patent_app_type] => utility [patent_app_number] => 15/346553 [patent_app_country] => US [patent_app_date] => 2016-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 37812 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15346553 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11602601 [patent_doc_number] => 20170119902 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-04 [patent_title] => 'ANTIBODY-DRUG CONJUGATE (ADC) AND METHOD FOR FORMING THE SAME' [patent_app_type] => utility [patent_app_number] => 15/341834 [patent_app_country] => US [patent_app_date] => 2016-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 19998 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15341834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11434862 [patent_doc_number] => 20170035881 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor' [patent_app_type] => utility [patent_app_number] => 15/297998 [patent_app_country] => US [patent_app_date] => 2016-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 99 [patent_figures_cnt] => 99 [patent_no_of_words] => 80733 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15297998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11419809 [patent_doc_number] => 20170027954 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'METHODS OF ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY' [patent_app_type] => utility [patent_app_number] => 15/290873 [patent_app_country] => US [patent_app_date] => 2016-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 15138 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15290873 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12049909 [patent_doc_number] => 20170326250 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/287891 [patent_app_country] => US [patent_app_date] => 2016-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 40427 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15287891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11677197 [patent_doc_number] => 09675706 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-06-13 [patent_title] => 'Immunoconjugates with an intracellularly-cleavable linkage' [patent_app_type] => utility [patent_app_number] => 15/267910 [patent_app_country] => US [patent_app_date] => 2016-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 28075 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15267910 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15394015 [patent_doc_number] => 10537644 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-21 [patent_title] => Covalent linkers in antibody-drug conjugates and methods of making and using the same [patent_app_type] => utility [patent_app_number] => 15/524487 [patent_app_country] => US [patent_app_date] => 2016-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 13764 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15524487 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11393989 [patent_doc_number] => 20170014525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY' [patent_app_type] => utility [patent_app_number] => 15/216407 [patent_app_country] => US [patent_app_date] => 2016-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 6592 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15216407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11381661 [patent_doc_number] => 20170007717 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-12 [patent_title] => 'DUOCARMYCIN ADCS FOR USE IN TREATMENT OF ENDOMETRIAL CANCER' [patent_app_type] => utility [patent_app_number] => 15/216366 [patent_app_country] => US [patent_app_date] => 2016-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 3487 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15216366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14729133 [patent_doc_number] => 10383947 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-20 [patent_title] => Pharmaceuticals in joint-linker configurations for treating pathological blood clots [patent_app_type] => utility [patent_app_number] => 15/212301 [patent_app_country] => US [patent_app_date] => 2016-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 36 [patent_no_of_words] => 26932 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 515 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15212301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11393987 [patent_doc_number] => 20170014522 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'CONJUGATES OF CYSTEINE ENGINEERED ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/195269 [patent_app_country] => US [patent_app_date] => 2016-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 33529 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15195269 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11100920 [patent_doc_number] => 20160297890 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-13 [patent_title] => 'ANTI-TROP2 ANTIBODY-DRUG CONJUGATE' [patent_app_type] => utility [patent_app_number] => 15/187179 [patent_app_country] => US [patent_app_date] => 2016-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 55449 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15187179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11323874 [patent_doc_number] => 20160354485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-08 [patent_title] => '1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT' [patent_app_type] => utility [patent_app_number] => 15/182444 [patent_app_country] => US [patent_app_date] => 2016-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 79828 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15182444 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12015852 [patent_doc_number] => 09808537 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-07 [patent_title] => 'Antibody-drug conjugate' [patent_app_type] => utility [patent_app_number] => 15/180203 [patent_app_country] => US [patent_app_date] => 2016-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 92930 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15180203 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12746215 [patent_doc_number] => 20180140572 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => COMPOSITIONS COMPRISING A CANCER STEMNESS INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT FOR USE IN TREATING CANCER [patent_app_type] => utility [patent_app_number] => 15/579013 [patent_app_country] => US [patent_app_date] => 2016-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18351 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15579013 [rel_patent_id] =>[rel_patent_doc_number] =>)